Purchase this article with an account.
C. Chen, Y. He; Evaluation of Nepafenac Treatment of Cystoid Macular Edema. Invest. Ophthalmol. Vis. Sci. 2009;50(13):1379.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the effectiveness of Nepafenec 0.1% treatment of cystoid macular edema (CME) in the improvement of visual acuity and reduction of foveal retinal nerve fiber layer (RNFL) thickness.
This retrospective, interventional, consecutive case series was conducted at UT Southwestern Clinic and Parkland Memorial Hospital in Dallas, TX from January 2007 to December 2008, of patients with a new diagnosis of CME treated initially with nepafenac alone or in combination with topical steroids. Data on pre- and post-treatment best corrected Snellen visual acuity and foveal retinal thickness measured by optical coherence tomography (OCT) was obtained; exclusion criteria included prior treatment with posterior subtenon or intravitreal steroid agents.
Eighteen patients (mean age 71.1 years, range 51 to 89 years, 39% male) treated with nepafenac (8 alone, 1 in combination with loteprednol etabonate 0.5%, 9 with prednisolone acetate 1%) for pseudophakic or idiopathic CME were evaluated. Mean acuity improved from 20/82 to 20/43 after treatment (P=0.0010) with a mean improvement of 2.1 Snellen lines. Foveal retinal thickness was 383.6 and 254.9 microns before and after treatment, respectively (P=0.0004), with a mean reduction of 129 microns. Average treatment duration was 9.4 wks.
This study suggests that Nepafenac 0.1% alone or in combination with topical steroids is effective in the treatment of CME in the improvement of visual acuity and reduction of foveal retinal thickness.
This PDF is available to Subscribers Only